An International, Multicenter, Non-interventional Post-Authorization Safety Study to Evaluate the Effectiveness and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) treated in Real-World Settings (MagnetisMM-16) First published 25/08/2023 Last updated 15/07/2024 EU PAS number:EUPAS106401 Study Ongoing